Adverum_Primary_Medium.png
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
May 17, 2022 16:05 ET | Adverum Biotechnologies, Inc.
- Human equivalent ADVM-022 dose of 6E10 vg/eye provided therapeutic levels of aflibercept in NHPs - Oral encore presentation to highlight ADVM-022 reductions in mean annualized anti-VEGF...
ultragenyx-CMYK.png
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
May 17, 2022 08:00 ET | Ultragenyx Pharmaceutical Inc.
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET | Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Adverum_Primary_Medium.png
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
May 12, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Freeline_Logo_Red_RGB.jpg
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022 16:01 ET | Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update and First Quarter 2022 Financial Results
May 06, 2022 06:33 ET | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is...
ibn-iw-globe-2.png
IBN’s BioMedWire to Serve as Media Sponsor for the Upcoming 2nd Annual Gene Therapy Patient Engagement Summit
May 04, 2022 09:35 ET | InvestorBrandNetwork (IBN)
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- via BioMedWire -- IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 02, 2022 07:30 ET | Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
May 01, 2022 14:15 ET | Adverum Biotechnologies, Inc.
- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81%...